Last reviewed · How we verify

Midazolam and propofol

Ain Shams University · FDA-approved active Small molecule Quality 5/100

Midazolam and propofol is a Small molecule drug developed by Ain Shams University. It is currently FDA-approved. Also known as: Dormicum, Diprivan.

At a glance

Generic nameMidazolam and propofol
Also known asDormicum, Diprivan
SponsorAin Shams University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Midazolam and propofol

What is Midazolam and propofol?

Midazolam and propofol is a Small molecule drug developed by Ain Shams University.

Who makes Midazolam and propofol?

Midazolam and propofol is developed and marketed by Ain Shams University (see full Ain Shams University pipeline at /company/ain-shams-university).

Is Midazolam and propofol also known as anything else?

Midazolam and propofol is also known as Dormicum, Diprivan.

What development phase is Midazolam and propofol in?

Midazolam and propofol is FDA-approved (marketed).

Related